EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic

Kazufumi Nakamura iD, Takahiro Okumura iD, Seiya Kato, Kenji Onoue, Toru Kubo iD, Hidemichi Kouzu iD, Toshiyuki Yano iD, Takayuki Inomata iD

International Journal of Molecular Sciences · 24.09.2025 · 26 (19) · 9347

DOI: 10.3390/ijms26199347 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.09.2025. Verfasst von Kazufumi Nakamura und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Sarcomeres, Cardiac Myosins. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grant Program for Biomedical Engineering Research from the Nakatani Foundation, 2025 Grant Program for Biomedical Engineering Research from the Nakatani Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying hypercontractility at the sarcomere level. Recent advances in molecular understanding have led to the development of cardiac myosin inhibitors that directly modulate sarcomeric function by reducing myosin–actin cross-bridge formation and adenosine triphosphatase (ATPase) activity. Mavacamten and aficamten have shown promising results in phase 2 and 3 clinical trials, improving symptoms, exercise capacity, and left ventricular outflow tract gradients in patients with obstructive HCM. This review summarizes the current understanding of HCM pathophysiology, diagnostic strategies, and conventional treatments with a focus on the mechanisms of action of myosin inhibitors, clinical evidence supporting their use, and future directions for improvement. We also discuss their potential applications in non-obstructive HCM and the importance of precision medicine guided by genetic profiling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicSarcomeresCardiac MyosinsHumansAnimalsMyosins

Stichwörter der Autor:innen

aficamtenheart failurehypertrophic cardiomyopathymavacamtenmyosin inhibitorssarcomere

Substanzen

Cardiac MyosinsMyosins

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.
  • Center for Advanced Heart Failure, Okayama University Hospital, Okayama 700-8558, Japan.
  • Department of Advanced Cardiovascular Therapeutics, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
  • Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
  • Division of Pathology, Saiseikai Fukuoka General Hospital, Fukuoka 810-0001, Japan.
  • Department of Cardiovascular Medicine, Nara Medical University, Kashihara 634-8521, Japan.

ORCID-Profile: Kazufumi Nakamura, Takahiro Okumura, Toru Kubo, Hidemichi Kouzu, Toshiyuki Yano, Takayuki Inomata

Förderung

  • Grant Program for Biomedical Engineering Research from the Nakatani Foundation
  • 2025 Grant Program for Biomedical Engineering Research from the Nakatani Foundation

Zitieren

APA

Nakamura, K., Okumura, T., Kato, S., Onoue, K., Kubo, T., Kouzu, H., Yano, T., & Inomata, T. (2025). Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. International Journal of Molecular Sciences, 26(19), 9347. https://doi.org/10.3390/ijms26199347

Vancouver

Nakamura K, Okumura T, Kato S, Onoue K, Kubo T, Kouzu H, et al. Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic. International Journal of Molecular Sciences. 2025;26(19):9347. doi:10.3390/ijms26199347

BibTeX
@article{Nakamura2025,
  author = {Nakamura, Kazufumi and Okumura, Takahiro and Kato, Seiya and Onoue, Kenji and Kubo, Toru and Kouzu, Hidemichi and Yano, Toshiyuki and Inomata, Takayuki},
  title = {Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {19},
  pages = {9347},
  doi = {10.3390/ijms26199347}
}
Kostenlos starten →